The human microbiome and COVID-19: A systematic review

Abstract

Background Human microbiotas are communities of microorganisms living in symbiosis with humans. They play an important role in the host immune response to respiratory viral infection. However, evidence on the human microbiome and coronavirus disease (COVID-19) relationship is insufficient. The aim of this systematic literature review was to evaluate existing evidence on the association between the microbiome and COVID-19 in humans and summarize these data in the pandemic era. Methods We conducted a systematic literature review on the association between the microbiome and COVID-19 in humans by searching PubMed, Embase, and the Cochrane Library, CINAHL, and Web of Science databases for articles in English published up to October 31, 2020. The results were analyzed qualitatively. This study is registered with PROSPERO (CRD42020195982). Results Of the 543 articles identified by searching databases, 16 in line with the research objectives were eligible for qualitative review: eight sampled the microbiome using stool, four using nasopharyngeal or throat swab, three using bronchoalveolar lavage fluid, and one using lung tissue. Fecal microbiome dysbiosis and increased opportunistic pathogens were reported in COVID-19 patients. Several studies suggested the dysbiosis in the lung microbiome of COVID-19 patients with an abundance of opportunistic pathogens using lower respiratory tract samples. The association between COVID-19 severity and the human microbiome remains uncertain. Conclusion The human fecal and respiratory tract microbiome changed in COVID-19 patients with opportunistic pathogen abundance. Further research to elucidate the effect of alternation of the human microbiome in disease pathogenesis is warranted.

Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients: a retrospective cohort study in a Mediterranean area

“…The relationship between the microbiota and COVID-19 is an active and expanding field of research. Previous studies have been focused in the differences of the gut microbiota between COVID-19 and non-COVID19 patients, or its correlation with severity inflammatory markers [10,11]. However, there has been limited investigation into the relationship between microbial communities and COVID-19 clinical outcome.…”

“…Regarding microbiota and COVID-19 pathology, many published studies have focused on the differences between COVID-19 and non-COVID-19 patients, suggesting a possible role of the gut or respiratory microbiota in susceptibility to SARS-CoV-2 infection [10,11].…”

Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19

“…The whole world has been witnessing a devastating pandemic in the form of coronavirus disease 2019 (COVID- 19), caused by the SARS-CoV-2 virus [1][2][3][4][5][6][7][8][9][10][11][12], ever since it was first discovered in China's Wuhan city in 2019 [13][14][15][16][17]. As of 5 July 2021, there were~184 M individuals worldwide contaminated with this lethal viral disease and 3.98 M people dead.…”

Role of Multifunctional Cytoskeletal Filaments in Coronaviridae Infections: Therapeutic Opportunities for COVID-19 in a Nutshell

“…Such optimization requires taking into account the different susceptibilities of the different human populations to these drugs and to the combinations of them with other treatments. It also requires a better understanding of the relationship between metabolism, cytoskeletal dynamics, and viral infections, a relationship that may extend to the microbiome [ 56 ].…”